IPCA Laboratories share price
NSE: IPCALABBSE: 524494Pharmaceuticals & BiotechnologyMid Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,903.50.
- Next results date: the board meets on 5 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹49,556 Cr229th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 13 Aug 2026
- 37.8
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 6.1
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.31%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- 17.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- 17.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.07
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 3,18,78151.9% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 13 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹2,788 Crup 16.73%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹424 Crup 38.34%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 15.2%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 14 Nov | Dec 2024Filed 13 Feb | Mar 2025Filed 16 Jun | Jun 2025Filed 11 Aug | Sep 2025Filed 13 Nov | Dec 2025Filed 13 Feb | Mar 2026Filed 29 May | Jun 2026Filed 13 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,355 | 2,245 | 2,247 | 2,309 | 2,557 | 2,393 | 2,388 | 2,788 |
| Net profit | 246 | 276 | 64 | 233 | 281 | 364 | 307 | 424 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 10.4% | 12.3% | 2.8% | 10.1% | 11.0% | 15.2% | 12.8% | 15.2% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history.PE ratio and valuation history
At or below today's level on 66% of 2,353 trading days over the last 10 years.
At or below today's level on 88% of 1,968 trading days since Nov 2018.
At or below today's level on 71% of 1,968 trading days since Nov 2018.
At or below today's level on 61% of 2,468 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +7.0% | +54.7% | −31.1% | 0.4% |
| 3 years | +25.8% | +34.3% | −6.5% | 0.3% |
| 5 years | +11.3% | 0.0% | +11.0% | 0.4% |
Mutual funds holding it
159 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 71 of the 95 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 45
- CutCut. Funds that held fewer shares than at the end of the month before.
- 50
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 61
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 2
| Fund | |||
|---|---|---|---|
 HDFC Mid Cap FundHDFC Mutual Fund | 1,81,40,659 | 3.43% | ₹3,495.7 Cr |
 Kotak Mid Cap FundKotak Mahindra Mutual Fund | 1,23,48,047 | 3.57% | ₹2,379.5 Cr |
 Axis Midcap FundAxis Mutual Fund | 40,05,425 | 2.30% | ₹771.8 Cr |
 Nippon India Growth Mid Cap FundNippon India Mutual Fund | 31,00,000 | 1.19% | ₹597.4 Cr |
 DSP Midcap FundDSP Mutual Fund | 28,75,353 | 2.84% | ₹554.1 Cr |
| Kotak Large & Mid Cap FundKotak Mahindra Mutual Fund | 25,25,000 | 1.59% | ₹486.6 Cr |
| HDFC Balanced Advantage FundHDFC Mutual Fund | 24,97,123 | 0.47% | ₹481.2 Cr |
| DSP Small Cap FundDSP Mutual Fund | 23,81,239 | 2.14% | ₹458.9 Cr |
 Edelweiss Mid Cap FundEdelweiss Mutual Fund | 18,33,465 | 1.84% | ₹353.3 Cr |
| DSP Healthcare FundDSP Mutual Fund | 15,82,807 | 8.13% | ₹305.0 Cr |
Peers and competitors
Pharmaceuticals, 215 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to IPCA Laboratories in market cap. 1 company in its own group left out: one owns more than half of the other, directly or through a company it controls, or one owner more than half of both.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Glenmark PharmaceuticalsGLENMARK | 61,147 | 34.0 | 5.8 | 12.5 | +32.9% | +138.4% | 18.6% | 39.8% | 0.12% |
 Alkem LaboratoriesALKEM | 59,149 | 27.4 | 4.3 | 19.5 | +13.4% | −5.6% | 16.7% | 16.5% | 1.07% |
 Abbott IndiaABBOTINDIA | 53,187 | 32.9 | 11.1 | 25.9 | +6.3% | +11.2% | 35.9% | 39.6% | 2.62% |
 BioconBIOCON | 52,721 | 106.4 | 1.5 | 18.2 | +9.8% | +28.6% | 1.8% | 2.9% | 0.15% |
 Gland PharmaGLAND | 46,645 | 41.3 | 4.5 | 24.9 | +17.6% | +46.5% | 11.6% | 12.4% | 0.71% |
 Ajanta PharmaAJANTPHARM | 41,035 | 36.2 | 9.1 | 28.0 | +20.2% | +22.0% | 27.3% | 27.2% | 1.83% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 40,737 | 38.1 | 18.0 | 29.1 | +5.8% | +12.4% | 50.6% | 56.3% | 2.37% |
 Emcure PharmaceuticalsEMCURE | 33,586 | 33.2 | 6.8 | 17.5 | +18.4% | +35.9% | 21.5% | 25.2% | 0.20% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 7 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹6.00 |
| 5 Aug 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹2.00 |
| 27 Nov 2024 | Interim | ₹2.00 |
| 6 Aug 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹2.00 |
| 22 Nov 2023 | Interim | ₹2.00 |
| 22 Nov 2022 | Interim | ₹4.00 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Aug 2026
IPCA Laboratories share price by year
Each calendar year to 2025.IPCA Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,418.90 | −16.3% | 1,744.05 | 1,268.70 |
| 2024 | 1,695.20 | +52.3% | 1,703.25 | 1,077.70 |
| 2023 | 1,113.15 | +32.0% | 1,149.70 | 675.00 |
| 2022 | 843.10 | −22.2% | 1,099.90 | 843.10 |
| 2021 | 1,083.40 | −1.0% | 1,318.75 | 900.45 |
| 2020 | 1,094.40 | +92.6% | 1,184.05 | 569.18 |
| 2019 | 568.13 | +41.7% | 579.85 | 361.50 |
| 2018 | 401.05 | +34.1% | 403.15 | 277.55 |
| 2017 | 299.15 | +12.2% | 323.23 | 204.40 |
| 2016 | 266.53 | −28.2% | 371.15 | 203.70 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 1,892.00 | 1,979.80 | 1,857.70 | 1,953.30 | 1,918.99 | 3,18,781 | 51.9% |
| 22 Oct 2026 | 1,898.00 | 1,952.00 | 1,884.20 | 1,903.50 | 1,918.58 | 3,27,011 | 49.5% |
| 21 Oct 2026 | 1,810.00 | 1,949.90 | 1,797.60 | 1,918.90 | 1,883.27 | 5,11,090 | 39.2% |
| 19 Oct 2026 | 1,832.60 | 1,853.90 | 1,797.00 | 1,814.50 | 1,827.22 | 1,67,626 | 52.6% |
| 16 Oct 2026 | 1,907.10 | 1,907.10 | 1,813.20 | 1,832.60 | 1,845.22 | 2,15,600 | 50.7% |
| 15 Oct 2026 | 1,888.00 | 1,930.00 | 1,888.00 | 1,913.10 | 1,912.92 | 1,66,493 | 65.7% |
| 14 Oct 2026 | 1,889.90 | 1,929.00 | 1,863.20 | 1,911.60 | 1,889.09 | 2,05,496 | 42.8% |
| 13 Oct 2026 | 1,908.90 | 1,940.00 | 1,861.40 | 1,919.20 | 1,907.78 | 3,41,431 | 65.0% |
| 12 Oct 2026 | 1,921.80 | 1,940.00 | 1,892.00 | 1,899.90 | 1,910.70 | 1,75,831 | 57.7% |
| 9 Oct 2026 | 1,942.90 | 1,952.50 | 1,905.00 | 1,915.40 | 1,921.92 | 94,285 | 52.7% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 10 Jan 2022 | Split | 0.5000 | Each share became 2. |
| 22 Mar 2010 | Split | 0.2000 | Each share became 5. |
About IPCA Laboratories
Ipca Laboratories Limited is an Indian pharmaceutical company. It makes and sells formulations, which are finished medicines, and active pharmaceutical ingredients (APIs) and drug intermediates, which are the chemicals that go into them. It was incorporated in 1949.
In India, the company sells branded formulations through 22 marketing divisions that focus on key therapeutic segments, with a portfolio of about 172 brands. Its products are exported to over 100 countries. It markets branded formulations through its own field force in Africa, in Asian countries such as Nepal, Sri Lanka, Myanmar, the Philippines and Vietnam, and in Russia, Kazakhstan and Belarus. In the United States, Unichem Pharmaceuticals (USA) Inc., a step-down subsidiary, markets and distributes formulations made by the company. Most of its international API customers are end-user formulations manufacturers.
Its works are in Madhya Pradesh, Gujarat, Maharashtra, Uttarakhand, Sikkim and the Union Territory of Dadra and Nagar Haveli and Daman and Diu. A new drug intermediates and API plant at Hingni in Wardha, Maharashtra, has started commercial production. The company has research and development centres at Mumbai, Ratlam, Athal (Silvassa) and Ranu (Vadodara). It has also set up a facility at Pithampur for monoclonal antibodies, with six candidates in development.
The company has one listed Indian subsidiary, Unichem Laboratories Limited, which was incorporated in Mumbai in 1962. It also has overseas subsidiaries, including one set up in Germany to hold product registrations and distribute generic formulations. The board includes three promoter directors. A promoter is the person or group that set up a company or controls it. They are the Executive Chairman, the Managing Director and CEO, and an Executive Director.
- Legal name
- IPCA Laboratories Limited
- NSE symbol
- IPCALAB
- BSE code
- 524494
- ISIN
- INE571A01038
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- May 1994 on BSE, Feb 1995 on NSE
- Face value
- ₹1
- CIN
- L24239MH1949PLC007837
- Corporate identity number, the registrar of companies' code for it